Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-215301 · Präparat HOS-155418
15 Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with (dose) Cmax, Cmin with confidence efavirenz intervals if availablea (mechanism) Vigabatrin/efavirenz Interaction not studied. Clinically No dose adjustment is necessary Gabapentin/efavirenz significant interactions are not for any of these medicinal expected since vigabatrin and products. gabapentin are exclusively eliminated unchanged in the urine and are unlikely to compete for the same metabolic enzymes and elimination pathways as efavirenz. ANTIDEPRESSANTS Selective Serotonin Reuptake Inhibitors (SSRIs) Sertraline/efavirenz Sertraline: Sertraline dose increases should (50 mg once daily/600 mg once AUC: ↓ 39% (↓ 27 to ↓ 50) be guided by clinical response. daily) Cmax: ↓ 29% (↓ 15 to ↓ 40) No dose adjustment is necessary Cmin: ↓ 46% (↓ 31 to ↓ 58) for efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vigabatrin (HOS-115599) gabapentin (HOS-090745) serotonin (HOS-085477) sertraline (HOS-086247)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage e27e9ae72c851e114aa5c2ee81c0dc43bac54fa507bcdb52f0b715be7d40555f · Zeichen 43513–44993 im Abschnitt